Results 91 to 100 of about 71,439 (210)

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BMC Cancer, 2007
Background Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment.
Colin Guillaume, Copin Marie, Scherpereel Arnaud, Makris Demosthenes, Brun Luc, Lafitte Jean, Marquette Charles   +6 more
doaj   +1 more source

Dynamics of cancer recurrence

, 2013
Mutation-induced drug resistance in cancer often causes the failure of therapies and cancer recurrence, despite an initial tumor reduction. The timing of such cancer recurrence is governed by a balance between several factors such as initial tumor size ...
Foo, Jasmine, Leder, Kevin
core   +1 more source

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution' [PDF]

, 2017
No abstract ...
Daniel J Murphy, HG Colt, J Mazieres, JC Wan, JP Pignon, K Suzawa, Kevin G Blyth, L Calman, M Jamal-Hanjani, M Schuler, TD Crabtree, WC Hanna   +11 more
core   +1 more source

Pulmonary Cryptococcal Infection Complicating Gefitinib Therapy in a Patient With EGFR L858R‐Positive Lung Adenocarcinoma: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In patients with EGFR‐mutant lung adenocarcinoma receiving gefitinib or other EGFR‐TKIs, the development of new pulmonary nodules should not be hastily attributed to disease progression; secondary pulmonary cryptococcosis should be considered in the differential diagnosis.
Yun Wang, Qianyu Wang, Jiangrong Liao, Yuxiang Zhou, Fang Yang, Gui feng Li, Chunyan Wu, Ting Jiang   +7 more
wiley   +1 more source

Proteomic and phosphoproteomic analysis reveals that neurokinin-1 receptor (NK1R) blockade with aprepitant in human keratinocytes activates a distinct subdomain of EGFR signaling: Implications for the anti-pruritic activity of NK1R antagonists [PDF]

, 2019
Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions.
Boozalis, Emily, Burns, Robert F, Huang, Amy H, Khanna, Raveena, Krischak, Madison, Kwatra, Madan M, Kwatra, Shawn G, Nanni, Cory, Roberts, Callie M, Semenov, Yevgeniy R, Williams, Kyle A   +10 more
core   +2 more sources

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor 
Mutant Non-small cell Lung Cancer Cell Line H1650

Chinese Journal of Lung Cancer, 2012
Background and objective Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it’s the one of molecular targets in clinical treatment.
Ruili HAN, Xiaoli WANG, Diansheng ZHONG, Juan ZHAO, Zhe CHEN, Linlin SUN, Jing WANG, Jinbang ZHANG   +7 more
doaj   +1 more source

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. [PDF]

, 2016
Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments
A Basu, Alykhan F Shamji, Andrew Crenshaw, Andrew L Kung, Aristotle M Mannan, Aviad Tsherniak, Bang Wong, Barbara A Weir, Bradley R Taylor, C Ditchfield, Channing Yu, D Peck, E Comer, Griselda Metta Yvone, J Barretina, J Du, JM Korn, Joshua Z Gould, JP Koivunen, JT Lowe, Kenneth N Ross, KT Flaherty, LA Marcaurelle, Levi A Garraway, M Carmena, Melissa A Marton, MI Davis, Michael A Foley, Michelle A Palmer, MJ Garnett, MK Muellner, ML Sos, MW Karaman, NC Turner, OD Abaan, Pablo Tamayo, PD Andrews, SL Schreiber, SM Wilhelm, Stuart L Schreiber, SV Sharma, Todd R Golub, U McDermott, Wendy Winckler, XD Zhang, Yan-Ling Zhang   +45 more
core   +2 more sources

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, Volume 45, Issue 3, Page 455-475, May/June 2026.
ABSTRACT Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

BMC Cancer, 2011
Background This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD)
Sun Yu-Nien, McCoy Sheryl, Siu Lillian L, Welch Stephen, Desai Jayesh, Tebbutt Niall, Kotasek Dusan, Johnson Jessica, Adewoye Adeboye H, Price Timothy   +9 more
doaj   +1 more source